| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
IC50: 4.9 nM (IP6K2), 8.9 nM (IP6K1), 1320 nM (IP6K3)[1].
Inositol hexakisphosphate kinase (IP6K), including IP6K1, IP6K2, and IP6K3/IP6K6. UNC7467 is a potent inhibitor of IP6K with IC₅₀ values of 8.9 nM for IP6K1, 4.9 nM for IP6K2, and 1320 nM for IP6K3. IP6K catalyzes the formation of inositol pyrophosphates, which are signaling molecules involved in various cellular processes including metabolism, insulin signaling, and energy homeostasis. By inhibiting IP6K, UNC7467 reduces inositol pyrophosphate levels, leading to metabolic effects such as reduced body weight gain and improved glycemic control. |
|---|---|
| ln Vitro |
UNC7467 lowers inositol pyrophosphate levels in HCT116 cells at 2.5 μM for three hours. 5-InsP7 levels are lowered by 81% and 5-InsP8 levels by 63% after using UNC7467[1].
UNC7467 is a potent IP6K inhibitor with IC₅₀ values of 4.9 nM for IP6K2, 8.9 nM for IP6K1, and 1320 nM for IP6K6. It effectively reduces inositol pyrophosphate levels without significantly affecting other inositol phosphates. The compound’s selectivity for IP6K over other inositol phosphate kinases makes it a valuable tool for studying IP6K biology. Its in vitro activity has been characterized using enzyme inhibition assays with purified IP6K isoforms. |
| ln Vivo |
Diet-induced obesity, insulin resistance, and hepatic steatosis were all lessened in diet-induced obese mice treated with UNC7467 (5 mg/kg; ip; daily, for 4 weeks)[1]. At a dose of 5 mg/kg, UNC7467 (1–5 mg/kg; iv and ip; diet-induced obesity mice) shows a significant AUClast (6054 h·ng/mL for intravenous (iv) and 2527 h·ng/mL for intraperitoneal (ip)) and poor clearance (13.7 (mL/min)/kg)[1].
In vivo, UNC7467 reduced body weight gain in the context of a high-fat diet, decreased fat, ameliorated hepatic steatosis, and improved glycemic profiles in diet-induced obese mice. These effects are consistent with the role of IP6K in metabolism and energy homeostasis. The compound is applicable for obesity research and has been evaluated in preclinical models of metabolic disease. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. |
| Enzyme Assay |
Non-cell-based assays for UNC7467 include IP6K enzyme inhibition assays using purified recombinant IP6K isoforms. The enzyme is incubated with inositol hexakisphosphate (IP6) and ATP in the presence of various concentrations of UNC7467. The formation of inositol pyrophosphates (e.g., IP7) is measured using radiometric or HPLC-based methods. IC₅₀ values of 8.9 nM (IP6K1), 4.9 nM (IP6K2), and 1320 nM (IP6K3) are determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for UNC7467 use various cell lines to assess IP6K inhibition and its effects on inositol pyrophosphate levels. Cells are treated with UNC7467 at various concentrations, and intracellular inositol pyrophosphate levels are measured using HPLC or mass spectrometry. The compound’s effects on insulin signaling, glucose metabolism, and lipid metabolism can be assessed in hepatocytes or adipocytes. Cell viability is assessed using standard assays.
|
| Animal Protocol |
Animal/Disease Models: Diet-induced obesity (DIO) mice[1]
Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection; daily, for 4 weeks Experimental Results: Improved glycemic profiles, ameliorated hepatic steatosis, and decreased weight gain without altering food intake. Animal/Disease Models: Diet-induced obesity (DIO) mice[1] Doses: 5 mg/kg (pharmacokinetic/PK Analysis) Route of Administration: intravenous (iv) injection and intraperitoneal (ip) injection Experimental Results: 1.19 route iv ip Dose (mg/kg ) 5 5 AUClast (h*ng/mL) 6054 2527 CL (mL/min/kg) 13.7 In vivo studies of UNC7467 are conducted in diet-induced obese (DIO) mouse models. Mice are fed a high-fat diet and treated with UNC7467 via oral administration or injection. Body weight, fat mass, hepatic steatosis, and glycemic profiles are measured over time. Tissue samples are collected for histopathological examination and biomarker analysis. Pharmacokinetic parameters are determined from blood samples collected at various time points. |
| ADME/Pharmacokinetics |
UNC7467 has a molecular formula of C₂₀H₁₃NO₃ and a molecular weight of 315.32 g/mol. Purity is ≥99.0%. The compound is soluble in DMSO (12 mg/mL). Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. Shipping is performed with ice packs. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for UNC7467 are limited. In vivo studies in diet-induced obese mice showed that the compound was well tolerated at the doses tested. As an IP6K inhibitor, it may have effects on metabolism and energy homeostasis. The compound is intended for research use only and is not for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
UNC7467 is a potent, selective inositol hexakisphosphate kinase (IP6K) inhibitor with IC₅₀ values of 8.9 nM for IP6K1, 4.9 nM for IP6K2, and 1320 nM for IP6K3. It effectively reduces inositol pyrophosphate levels without significantly affecting other inositol phosphates. In vivo, UNC7467 reduced body weight gain, decreased fat, ameliorated hepatic steatosis, and improved glycemic profiles in diet-induced obese mice. The compound is applicable for obesity research and is intended for research use only.
|
| Molecular Formula |
C20H13NO3
|
|---|---|
| Molecular Weight |
315.32
|
| Exact Mass |
315.089
|
| CAS # |
2922283-43-8
|
| PubChem CID |
164887496
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.299±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)
|
| Boiling Point |
599.2±35.0 °C(Predicted)
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
440
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C2C=CC(C3C=CC=CC=3)=CC=2)=C2C=C(C(=O)O)C=CC2=N1
|
| InChi Key |
FGCSKRKOSIKUGT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H13NO3/c22-20(23)16-10-11-18-17(12-16)19(24-21-18)15-8-6-14(7-9-15)13-4-2-1-3-5-13/h1-12H,(H,22,23)
|
| Chemical Name |
3-(4-phenylphenyl)-2,1-benzoxazole-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 14.29 mg/mL (45.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1714 mL | 15.8569 mL | 31.7138 mL | |
| 5 mM | 0.6343 mL | 3.1714 mL | 6.3428 mL | |
| 10 mM | 0.3171 mL | 1.5857 mL | 3.1714 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
